Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: the First Real-word Evidence From China

NCT05044091 is registered in ClinicalTrials.gov with Xiaoxiang Chen as lead sponsor.

NCT NCT05044091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05044091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: the First Real-word Evidence From China
Lead sponsor
Xiaoxiang Chen
Phase
Observational
Overall status
Unknown status
Start date
September 15, 2021
Completion date
September 30, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hrd, ovarian cancer, parp inhibitor